您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
OX40L/TNFSF4/CD252 Recombinant Rabbit mAb (S-1337-18)

OX40L/TNFSF4/CD252 Recombinant Rabbit mAb (S-1337-18)

货号: S0B1128
价格: 600
规格: 25μl
介绍: -
其他: -
产品规格
  • 宿主来源

    Rabbit
  • 抗原名称

    OX40L/TNFSF4/CD252
  • 分子别名

    Tumor necrosis factor ligand superfamily member 4; Glycoprotein Gp34; OX40 ligand; TAX transcriptionally-activated glycoprotein 1; TXGP1
  • 免疫原

    Recombinant Protein
  • 细胞定位

    Membrane
  • Accession

    P23510
  • 克隆号

    S-1337-18
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG
  • 应用

    WB
  • 反应种属 ?

    Hu
  • 阳性样本

    HUVEC
  • 纯化方式

    Protein A
  • 浓度

    1 mg/ml
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
  • 储存条件

    12 months from date of receipt / reconstitution, -20 °C as supplied

稀释度
应用 稀释度 推荐种属
WB 1:1000 Hu
背景介绍
  • OX40L, also known as CD252, TNFSF4, or gp34, is a type II membrane protein that serves as the ligand for OX40 (CD134), a member of the tumor necrosis factor receptor (TNFR) superfamily. OX40L primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, binds to OX40 on activated T cells, enhancing their activation, proliferation, and survival. The OX40-OX40L interaction can promote the production of various cytokines and enhance the effector functions of T cells, contributing to immune responses against pathogens and tumor. OX40 signaling can influence the differentiation and function of various T cell subsets, including Th1, Th2, Th17, Tfh, and regulatory T cells (Tregs). Its role in enhancing T cell responses makes it a target for cancer immunotherapy. Agonistic antibodies targeting OX40 are being developed to stimulate T cell responses against tumors. In conditions like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, the OX40-OX40L interaction contributes to the pathogenesis by promoting inflammatory T cell responses. The OX40-OX40L pathway also plays a role in transplant rejection and graft-versus-host disease (GVHD), making it a potential target for therapeutic intervention in transplantation medicine.

  • 免疫印迹

    • WB result of OX40L/TNFSF4/CD252 Recombinant Rabbit mAb
      Primary antibody: OX40L/TNFSF4/CD252 Recombinant Rabbit mAb at 1/1000 dilution
      Lane 1: Raji whole cell lysate 20 µg
      Lane 2: HUVEC whole cell lysate 20 µg
      Negative control: Raji whole cell lysate
      Secondary antibody: Goat Anti-Rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution Predicted MW: 21 kDa
      Observed MW: 30 kDa